Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit

Author:

Altman Meghan O.1ORCID,Angel Matthew1,Košík Ivan1ORCID,Trovão Nídia S.23,Zost Seth J.4ORCID,Gibbs James S.1,Casalino Lorenzo5ORCID,Amaro Rommie E.5,Hensley Scott E.4ORCID,Nelson Martha I.2ORCID,Yewdell Jonathan W.1ORCID

Affiliation:

1. Cellular Biology Section, Laboratory of Viral Diseases NIAID, NIH, Bethesda, Maryland, USA

2. Division of International Epidemiology and Population Studies, Fogarty International Center, NIH, Bethesda, Maryland, USA

3. Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York City, New York, USA

4. Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

5. Department of Chemistry and Biochemistry and the National Biomedical Computation Resource, University of California, San Diego, La Jolla, California, USA

Abstract

Frequent mutation of its major antibody target, the glycoprotein hemagglutinin, ensures that the influenza virus is perennially both a rapidly emerging virus and a major threat to public health. One type of mutation escapes immunity by adding a glycan onto an area of hemagglutinin that many antibodies recognize. This study revealed that these glycan changes follow a simple temporal pattern. Every 5 to 7 years, hemagglutinin adds a new glycan, up to a limit. After this limit is reached, no net additions of glycans occur. Instead, glycans are swapped or lost at longer intervals. Eventually, a pandemic replaces the terminally glycosylated hemagglutinin with a minimally glycosylated one from the animal reservoir, restarting the cycle. This pattern suggests the following: (i) some hemagglutinins are evolved for this decades-long process, which is both defined by and limited by successive glycan addition; and (ii) hemagglutinin's antibody dominance and its capacity for mutations are highly adapted features that allow influenza to outpace our antibody-based immunity.

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Reference57 articles.

1. WHO. 2003. Influenza fact sheet no. 211. http://www.who.int/mediacentre/factsheets/2003/fs211/en/. Accessed 21 June 2018.

2. IMMUNITY TO INFLUENZA IN MAN

3. CDC. 2017. Vaccine effectiveness-how well does the flu vaccine work? https://www.cdc.gov/flu/about/qa/vaccineeffect.htm. Accessed 21 June 2018.

4. Carbohydrates of influenza virus. Structural elucidation of the individual glycans of the FPV hemagglutinin by two-dimensional 1H n.m.r. and methylation analysis.

5. Integrated Omics and Computational Glycobiology Reveal Structural Basis for Influenza A Virus Glycan Microheterogeneity and Host Interactions

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3